Orchid Pharma Ltd - Stock Valuation and Financial Performance

BSE: 524372 | NSE: ORCHPHARMA | Pharmaceuticals & Drugs | Small Cap

Orchid Pharma Share Price

1,797.65 70.90 4.11%
as on 24-Dec'24 16:59

DeciZen - make an informed investing decision on Orchid Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Orchid Pharma stock performance -

mw4me loader
P/E Ratio (SA):
76.97
Market Cap:
9,117.5 Cr.
52-wk low:
693.1
52-wk high:
1,850

Is Orchid Pharma Ltd an attractive stock to invest in?

1. Is Orchid Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Orchid Pharma Ltd is a below average quality company.

2. Is Orchid Pharma Ltd undervalued or overvalued?

The key valuation ratios of Orchid Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Orchid Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Orchid Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Orchid Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Orchid Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 4.2%0.1%-6.4%-3.4%-3.8%-4.3%-3.5%-1.9%8.8%9%-
Value Creation
Index
-0.7-1.0NANA-1.3-1.3-1.3-1.1-0.4-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,157879755644584481451557666819905
Sales YoY Gr.--24%-14.1%-14.7%-9.4%-17.6%-6.3%23.6%19.6%23.1%-
Adj EPS -20.2-27.9-41.1-38.43.7-18.8-24.2-14.35.817.823.4
YoY Gr.-NANANANA-603.2%NANANA207.6%-
BVPS (₹) 34.419.2-29.7-75.8-84.9195.5166.9166.1179.3240.2250.7
Adj Net
Profit
-172-248-366-34233.2-76.6-98.9-58.423.690.2118
Cash Flow from Ops. -2462113185.615.280.424.489.613.4131-
Debt/CF from Ops. -8.715.29.8573.5212.7718.6324.81-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -3.8%7%22.1%23.1%
Adj EPS NA36.7%NA207.6%
BVPS24.1%NA12.9%34%
Share Price 39.6% 221.3% 66.2% 150.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-55.6-81.3789.572.9-4.6-357.8-13.4-8.63.49.39.5
Op. Profit
Mgn %
18.419.812.26.510.6613.110.512.713.614.1
Net Profit
Mgn %
-14.8-28.2-48.4-535.7-15.9-21.9-10.53.51113.1
Debt to
Equity
7.318.8-11.8-4.8-4.30.70.70.40.50.10.1
Working Cap
Days
355691737735766616318271265249164
Cash Conv.
Cycle
458564251782151142140122119

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 9.50%

Sales growth is growing at healthy rate in last 3 years 22.05%

Sales growth is good in last 4 quarters at 21.80%

Net Profit has been subdued in last 3 years 0.00%

Latest Financials - Orchid Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 23.4 23.5
TTM Sales (₹ Cr.) 905 905
BVPS (₹.) 250.7 241.4
Reserves (₹ Cr.) 1,221 1,174
P/BV 7.17 7.45
PE 76.97 76.63
From the Market
52 Week Low / High (₹) 693.05 / 1849.95
All Time Low / High (₹) 3.04 / 2680.00
Market Cap (₹ Cr.) 9,118
Equity (₹ Cr.) 50.7
Face Value (₹) 10
Industry PE 44.4

Management X-Ray of Orchid Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Orchid Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales1,736879755644584481451557666819
Operating Expenses 1,416705663622590470392498582709
Manufacturing Costs28414713911410398688697103
Material Costs781419367331278200229314385484
Employee Cost 186837582797264606570
Other Costs 16557819512910030383552
Operating Profit 3201749222-611595984111
Operating Profit Margin (%) 18.4%19.8%12.2%3.4%-1.1%2.4%13.0%10.5%12.7%13.5%
Other Income 422519201724691931
Interest 5372943313107652333317
Depreciation 321143139133130118109875533
Exceptional Items 113-53-173025000390
Profit Before Tax -383-292-532-401-101-88-96-535592
Tax -192-17-48-4600000-3
Profit After Tax -191-274-484-355-101-88-96-535595
PAT Margin (%) -11.0%-31.2%-64.0%-55.2%-17.3%-18.4%-21.3%-9.5%8.3%11.6%
Adjusted EPS (₹)-22.4-30.8-54.4-39.9-11.4-21.7-23.5-12.913.518.7
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 439171-264-674-7557986816787321,218
Share Capital 85898989894141414151
Reserves 35482-353-763-8447576416376911,168
Minority Interest0000000000
Debt3,1413,0112,7562,5882,120504430231290134
Long Term Debt2,4942,3782,1571,8941,425504427208149120
Short Term Debt647634600694695032314114
Trade Payables2963534043272706069121129179
Others Liabilities 2804275659701,3588844647220
Total Liabilities 4,1563,9633,4613,2112,9931,4501,2241,0941,2231,552

Fixed Assets

Gross Block2,8902,8932,8931,4251,4251,2471,1761,1761,2201,297
Accumulated Depreciation1,1931,3531,492133263389506593647681
Net Fixed Assets1,6971,5401,4021,2911,161858670584573616
CWIP 282280288272278267104624
Investments 1251251251250015495069
Inventories242210197185167141151173229264
Trade Receivables29037524614514166132160212189
Cash Equivalents 39031325630132417219422257
Others Assets1,1311,11894689292118723011591131
Total Assets 4,1563,9633,4613,2112,9931,4501,2241,0941,2231,552

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity -37021131861580249013131
PBT -238-292-445-401-101-150-117-55492
Adjustment 999496576450235175164385442
Changes in Working Capital -6697188-36-11545-2758-95-3
Tax Paid -4700-7-4105-201
Cash Flow From Investing Activity 1,334-1-9-284516767113-27-316
Capex -82-1-9-6-7-40145-26-55
Net Investments 000-343714767-33-1-272
Others 1,4160012152410112
Cash Flow From Financing Activity -597-287-366330-250-165-21731167
Net Proceeds from Shares 741800040000392
Net Proceeds from Borrowing -484-27-128-10-1,044-125-205-110-209
Interest Paid -150-265-219-400-40-32-32-16
Dividend Paid 0000000000
Others -36-13-193907540201730
Net Cash Flow 367-76-571160-3-73-1418-18
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-41.19-89.85N/AN/AN/A-413.02-12.96-7.767.849.72
ROCE (%)4.20.08N/AN/AN/A-4.28-3.5-1.868.778.96
Asset Turnover Ratio0.390.220.210.190.190.220.340.480.570.59
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/A0.241.38
Working Capital Days
Receivable Days501371481108979809610289
Inventory Days789397108110117118106110110
Payable Days200282376403392301103110119116

Orchid Pharma Ltd Stock News

Orchid Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Orchid Pharma on 24-Dec-2024 16:59 is ₹1,797.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Dec-2024 16:59 the market cap of Orchid Pharma stood at ₹9,117.5.
The latest P/E ratio of Orchid Pharma as of 24-Dec-2024 16:59 is 76.97.
The latest P/B ratio of Orchid Pharma as of 24-Dec-2024 16:59 is 7.17.
The 52-week high of Orchid Pharma is ₹1,850 and the 52-week low is ₹693.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Orchid Pharma is ₹904.8 ( Cr.) .

About Orchid Pharma Ltd

Orchid Chemicals & Pharmaceuticals (Orchid) is pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was Incorporated in the year 1992 as a 100% export-oriented unit (EOU).

Orchid has employee strength of over 3700 people, out of which over 600 are scientists, technologists and other professionals.

The drug major has two manufacturing unit for APIs located at Alathur and Aurangabad and three facilities for fosage forms at Irungattukottai and Alathur. Besides this it two research and development centres located at Sholinganallur and Irungattukottai, Chennai.

It has formed an alliance with North China Pharmaceutical Corporation (NCPC), which is the largest pharmaceutical group in China to manufacture and market pharmaceuticals products.

The company has formed distribution and marketing alliance with various global pharmaceutical corporations including Apotex, Actavis, Hospira and Dava, among others.

Orchid owns two subsidiaries, whose core focus are on drug discovery and development namely Orchid Research Laboratories in Chennai and Bexel Pharmaceuticals in the US. Besides this, it also has subsidiary such as Orgenus Pharma Inc (USA), Orchid Pharmaceuticals Inc (USA), Ogna Farma (South America) and Orchid Europe.

During March 2010, Orchid Chemicals & Pharmaceuticals had completed the transaction for sale and transfer of Orchid's generic injectable finished dosage forms Pharmaceuticals business to Hospira Healthcare India, a subsidiary of Hospira, Inc.

In January 2011, Orchid Chemicals & Pharmaceuticals had signed a memorandum of understanding with Great Lakes Institute of Management for setting up a centre of excellence in technopreneurship at Great Lakes campus near Chennai. The MoU was signed in the presence of APJ Abdul Kalam, former President of India, during the inauguration of Great Lakes' B-school festival, L’Attitude 13° 05’.

In April 2011, Orchid Chemicals had attained an out-of-court settlement with world's largest drug maker Pfizer Inc to sell a low-cost version of the American firm's patented anti-depressant drug, Effexor XR, (extended release) in the US market this fiscal.

In 2012
 - Orchid Pharma exit its Chinese JV with NCPC
 - Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million

In 2013
- Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics

Products

Active Pharmaceutical Ingredients- Orchid develops a wide range of APIs in category of oral cephalosporins, betalactams, special nutraceuticals, etc.

Formulations- Under this the company is engaged in developing formulation in various segment such anti-infectives, anti-oxidants, oral anti-diabetics, etc.

Awards


Orchid was awarded as the Top Indian Public Limited Company in Patent at the 5th National Intellectual Property Award 2013, organized by CII in partnership with the Department of Industrial Policy & Promotion and Indian Intellectual Property Office, Government of India.
Orchid received EXIM Achievement Award 2012 for its meritorious export performance by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred with the Export Excellence Award 2010-11 by MEPZ – Special Economic Zone, Government of India.

Orchid received EXIM Achievement Award 2011 for its meritorious export performance under the category Air Exports by The Tamil Chamber of Commerce, Chennai.

Orchid was conferred the Gold Patent Award for the year 2010-11 in recognition of its commendable contribution to R&D in Drug Discovery Sector by the Pharmaceutical Export Promotion Council. The award was presented by Shri. N. Kiran Kumar Reddy, Hon’ble Chief Minister of Andhra Pradesh.
Orchid was awarded IGCW – 2011 Green Innovation Award for the outstanding research in the field of Green Chemistry & Engineering in 2011.

Orchid was conferred the Shrishti Good Green Governance (G3) Award in 2011. The award was presented by Mr. Salman Khurshid, Minister of Water Resources & Minority Affairs, Government of India.

In 2010, for ""Outstanding Achievement in Environment Management in the Chemical sector"", Orchid was conferred with the Silver Award by Greentech Foundation.

Orchid was awarded the ""Siemens Ecovatives-IBN Live Award 2010"" in recognition of our outstanding initiatives in Energy Management (Low Energy and Natural Resource Conservation).

In 2010, Orchid’s Alathur API facility received the Bureau of Energy Efficiency (BEE) Certificate of Merit on Energy Efficiency by the Ministry of Power, Government of India.

Orchid’s endeavour in the area of energy conservation was recognised with the “Excellent Energy Efficient Unit” in the 9th Energy Efficiency Summit 2010 organised by the CII (Confederation of Indian Industries). This award was recently presented by Mr.Ajay Mathur, Director General of Bureau of Energy Efficiency, Ministry of Power, and Government of India.

Orchid’s Aurangabad facility received the Dr.R J Rathi Award for Environment Pollution & Control in industries in Maharashtra for the year 2010 (constituted by Maharashtra Chamber of Commerce Industries & Agriculture, Pune)

Orchid's Alathur facility was awarded Certificate of Appreciation by the National Safety Council of India (Safety Awards - 2011) in recognition of its appreciable achievement in Occupational Safety & Health during the assessment period of three years from 2008-10.

In 2011, Orchid received the ""Green Tech Gold Safety Award"" by Greentech Foundation. The award was presented by Dr RK Srivastav, Director General of Health Services, Ministry of Health & Family Welfare, Gov of India  and Mr Kamaleshwar Sharan, President, Greentech Foundation.

Orchid’s Alathur facility received the Greentech Safety Award 2010 (Silver award) in pharmaceutical sector for outstanding achievement in Safety Management given by Greentech Foundation.

Orchid was awarded the ""Certificate of Merit Award"" for 2010 by the CII for Excellence in Environment, Health and Safety.

Orchid Research Laboratories (the discovery subsidiary of Orchid) won the Partner of Choice Award for Contract Research - Collaborative Drug Discovery by Frost & Sullivan in April 2007.

The company also bagged Gold Award for Excellence and Business Prestige was awarded at the Quality Summit 2003, New York.

 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.